메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Neurophet and The Florey Strengthen Research Collabora…

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management Joint research to enhance dementia diagnosis using the brain neurodegeneration imaging software 'Neurophet AQUA' SEOUL, South Korea, Nov. 25, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 25th that it will collaborate with the Florey Institute of Neuroscience and Mental Health (The Florey) in Australia on joint research using its brai
- 김갑성 기자
- 2025-11-25 22:00
Mabwell Announces First-Patient Dosing for Novel CDH17-Targ…

SHANGHAI, Nov. 25, 2025 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for advanced solid tumors. This Phase I/II clinical trial (CTR20254163) aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of 7MW4911 in patients with advanced solid tumors. Previously, 7MW4911 had received IND clearance from F
- 김갑성 기자
- 2025-11-25 22:00
JUNG KWAN JANG Launches Black Friday & Holiday Promotions a…

[ 메디채널 김갑성 기자 ] Global wellness brand JUNG KWAN JANG rolls out major Black Friday and holiday-season promotions across the U.S. New products including EVERYTIME and Hong Sam Won gain momentum on Amazon, Costco, and other major retail channels Korean Red Ginseng rises worldwide as a leading natural, non-GMO, gluten-free health ingredient backed by scientific benefits CERRITOS, Calif., Nov. 25, 2025 -- The world's No.1 ginseng brand, JUNG KWAN JANG, is strengthening its leadership in the U.S. wellness market with nationwide Black Friday and holiday promotions, along with the laun
- 김갑성 기자
- 2025-11-25 21:00
Hong Kong to Host International Summit on Heart and Brain He…

HONG KONG, Nov. 25, 2025 -- The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) will bring together global leaders to discuss cutting-edge research, innovative medical products, and cross-border collaborations to accelerate progress toward advanced cerebro-cardiovascular care worldwide. Hosted by the InnoHK Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE), the summit will serve as a unique and premium platform uniting leading clinicians, engineers, entrepreneurs, and investors. This year's event features distinguished experts and le
- 김갑성 기자
- 2025-11-25 20:54
TCL CSOT Unveils "2025 Eye-Care Technology White Paper", Se…

SUZHOU, China, Nov. 25, 2025 -- TCL China Star Optoelectronics Technology (TCL CSOT), a global leader in advanced display technologies and a subsidiary of TCL Technology (000100.SZ), in collaboration with the National Engineering Research Center for Ophthalmology & Optometry of Wenzhou Medical University in China, and leading industry partners including Lenovo, CVTE, TAL Education, the China Institute of Standardization, SGS, officially released the "2025 Eye-Care Technology White Paper" (the White Paper) at the TCL CSOT Display Health Industry Seminar. The White
- 김갑성 기자
- 2025-11-25 18:01
메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp…

모구 형질세포양 수지상세포 종양(BPDCN) 환자들에게 중요한 발견을 담은 2건의 구두 발표를 포함하여 총 5개의 초록에 걸친 데이터 공개 BPDCN은 피부, 골수, 혈액에 주로 영향을 미치는 매우 공격적인 희귀 혈액암 이탈리아 피렌체 및 뉴욕, 2025년 11월 25일 -- 세계적인 제약·진단 기업인 메나리니 그룹(Menarini Group)과 메나리니 그룹의 전액 출자 자회사이자 암 환자들에게 혁신적인 종양 치료제를 제공하는 데 주력하는 스템라인 테라퓨틱스(Stemline Therapeutics)가 오늘 12월 6일부터 9일까지 올랜도에서 열리는 미국혈액학회(American Society of Hematology, ASH) 연례 학술대회에서 ELZONRIS® (tagraxofusp-erzs) 관련 신규 데이터를 발표한다고 밝혔다. 발표 중에는 tagraxofusp, azacitidine, venetoclax 3제 요법 결과를 다루는 구두 세션이 포함된다. 이 요법은 높은 반응률과 이식 전 단계(bride to transplant) 도달률, 그리고 내약성을 함께 보여 모구 형질세
- 김갑성 기자
- 2025-11-25 17:44
Mazdutide 9mg Supplementary Application Accepted for Rev…

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by
- 김갑성 기자
- 2025-11-25 17:00
FROM MEDICAL SUPPLIER TO MULTI-INDUSTRY LEADER: LIVINGSTONE IN…

SYDNEY, Nov. 25, 2025 -- One of Australia's largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries. Livingstone International supplies more than 65,000 essential health, hygiene, education, beauty, and hospitality products to industries including aged care, schools and universities, hair and skin clinics, pharmacy, dental, mining, and government. Livingstone International Managing Director, Daniel Linn, said the company has no
- 김갑성 기자
- 2025-11-25 05:00
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Pla…

[ 메디채널 김갑성 기자 ] The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating ad
- 김갑성 기자
- 2025-11-25 00:30
Menarini Group Announces New Data on ELZONRIS® (tagraxo…

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy and NEW YORK, Nov. 24, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology
- 김갑성 기자
- 2025-11-24 23:34

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분